NCT03423108 (EDDIE) is a NA clinical trial of G150 in Type2 Diabetes, sponsored by Hospital de Clinicas de Porto Alegre.

Who is sponsoring NCT03423108?

NCT03423108 is sponsored by Hospital de Clinicas de Porto Alegre.

What drugs are being tested in NCT03423108?

Interventions in NCT03423108: G150, G300.

What condition does NCT03423108 study?

NCT03423108 studies Type2 Diabetes.

Is NCT03423108 still recruiting?

NCT03423108 is currently status unknown. Last updated 6 September 2018.

Last reviewed 2018-09-06 · How we verify

NCT03423108: EDDIE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise Dose-response for Diabetes in the Elderly

Status unknown NA Last updated 6 September 2018

What this trial tests

NA trial testing G150 in Type2 Diabetes in 132 participants. Status unknown.

Timeline

10 September 2018

Primary endpoint
1 January 2019

1 August 2020

Quick facts

Lead sponsor	Hospital de Clinicas de Porto Alegre
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	132
Start date	10 September 2018
Primary completion	1 January 2019
Estimated completion	1 August 2020
Sites	1 location across Brazil

Drugs / interventions tested

G150
G300

Conditions studied

Type2 Diabetes — all drugs for Type2 Diabetes →

Sponsor

Hospital de Clinicas de Porto Alegre

Who can join

60 and older, any sex, with Type2 Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One-center randomized, three-arm, parallel, superiority, controlled trial in 132 elderly outpatients with type 2 diabetes. Two different combined exercise training doses (300min/week vs 150min/week) will be compared against usual care. The entire study length will last 24 weeks, and assessments will be conducted at baseline, previously to the group allocation, at 12 weeks and at 24 weeks just after the treatments' end. The study's primary outcome is the glycated hemoglobin level at 24 weeks. Secondary outcomes of clinical relevance to type 2 diabetes and elderlies will also be acquired.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Type2 Diabetes

Currently open trials in the same condition.

NCT05277558 — Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D) · recruiting
NCT05015283 — Efficacy and Safety of One-anastomosis Versus Roux-en-Y Gastric Bypass for Type 2 Diabetes Remission · NA · recruiting
NCT05006508 — Prevention With the Health and Lifestyle Tool · NA · active not recruiting
NCT04717050 — Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity · NA · active not recruiting
NCT05220917 — Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study · active not recruiting

Other Hospital de Clinicas de Porto Alegre trials

Trials by the same sponsor.

NCT07469722 — POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure · Phase 2, PHASE3 · not yet recruiting
NCT07264179 — Tracheal Cuff Pressure and Postoperative Complications: A Prospective Observational Study. · not yet recruiting
NCT07052058 — Triple-Blind Randomized Clinical Trial of Tocilizumab vs Placebo: Potential Use of an IL-6 Antagonist as an Adjuvant to · Phase 2 · not yet recruiting
NCT06953128 — General Versus Regional Anesthesia in Peripheral Arterial Surgery · NA · not yet recruiting
NCT06934707 — Meal Frequency and Glycemic Control in Individuals With Type 1 Diabetes · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03423108 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hospital de Clinicas de Porto Alegre
Last refreshed: 6 September 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03423108.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing